Product Update

Deltex Medical Group PLC
04 May 2005


                            Deltex Medical Group plc

     CardioQ reduces hospital stay by 2 days in colorectal surgery patients

4 May 2005:  Deltex Medical Group plc ('Deltex Medical' and the 'Company'),
today announces the results of a double-blinded prospective randomised
controlled clinical trial using its CardioQ(TM) haemodynamic monitoring system 
on post-operative colorectal patients.

The trial was undertaken by surgeons and anaesthetists at the Freeman Hospital
in Newcastle-upon-Tyne.  The first results to come from the study were presented
this week at the American Society of Colon and Rectal Surgeons meeting in
Philadelphia.  In the trial 108 patients undergoing elective colorectal surgery
were divided into two groups of 54 each.  The control group were given fluids
peri-operatively at the anaesthetist's discretion whereas the treatment group
were given fluids based on an algorithm guided by the CardioQ.

The statistically significant results of the study presented in Philadelphia
included a reduction in major post surgical complications in the CardioQ group
with only 1% of patients suffering such a complication compared to 13.7% in the
control group.  The average (median) hospital stay was seven days for CardioQ
patients compared to nine days in the control group.  Further details are
expected to be given at future clinical meetings and on publication of the full
study results.  The trial concluded that fluid optimisation using the CardioQ
leads to shorter hospital stays and a decrease in major morbidity with
consequent major implications for the management of patients in fast-track
regimens.

Deltex Medical's Chief Executive, Andy Hill commented:

'The results of this study have a number of important implications for the
Company.  The study adds to the substantial amount of positive evidence
supporting the use of the CardioQ in moderate and major surgery in general and,
following a similar study from Worthing Hospital announced last September, in
colorectal surgery as a stand-alone speciality.  This allows us to market the
benefits of the CardioQ in the treatment of bowel cancer as well as in
peri-operative anaesthesia.

'As the study was the first one using the CardioQ to be led by surgeons rather
than anaesthetists, its findings should reach a wider audience than previous
studies at a time when colorectal surgeons are being increasingly scrutinised
with regard both to the quality of outcome for their patients and the total cost
of the patient's surgery and hospital stay.'

For further information, please contact:-

Deltex Medical Group plc                               01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics                                     0207 831 3113
David Yates
Lucy Briggs


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange